Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Neogenomics (NEO) Non-Current Deffered Revenue (2017 - 2018)

Historic Non-Current Deffered Revenue for Neogenomics (NEO) over the last 2 years, with Q3 2018 value amounting to $1.2 million.

Neogenomics' Non-Current Deffered Revenue changed N/A to $1.2 million in Q3 2018 from the same period last year, while for Sep 2018 it was $1.2 million, marking a year-over-year change of. This contributed to the annual value of $283000.0 for FY2017, which is N/A changed from last year.
Neogenomics' Non-Current Deffered Revenue amounted to $1.2 million in Q3 2018.
In the past 5 years, Neogenomics' Non-Current Deffered Revenue ranged from a high of $1.2 million in Q3 2018 and a low of $283000.0 during Q4 2017